KMT2A and acute myeloid leukemia: As shown in Fig. 4h, the treatment of primary patient-derived AML samples, including both MLL-r and non-MLL-r subtypes, with WNK463 led to reduced p-OXSR1/p-STK39 (Fig. 4h).